# US 12,178,797 B2 · Formulation for pain management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,797 B2
- Document ID: US12178797B2
- Status: Granted
- Kind: B2
- Application number: 17/218,329
- Filed: 2021-03-31
- Published: 2021-08-05
- Granted: 2024-12-31
- Earliest claimed: 2019-05-03
- Applicants: Zyus Life Sciences Inc.
- Inventors: Brenton Harold Zettl
- Web page: https://patentgrep.com/patent/US12178797B2

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method of pain management is described, for use by individuals experiencing pain, comprising administration of a formulation comprising a plurality of cannabinoids. Primary cannabinoids are present in the formulation in amounts according to a weight ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of using the formulation, doses and dosage forms are described, including a formulation pairing in which a first formulation comprising CBC:CBD at 1:5 to 5:5 is utilized at certain times of day when psychoactive effects of THC are not desired, and a second formulation comprising THC:CBC:CBD is used at other times of day, typically evening or bedtime.

## Claims

### Claim 1

A formulation pairing for use in a method of pain management by a subject in need thereof, said formulation pairing comprising a first formulation and a second formulation for use at different times of a multi-dose daily regimen;
wherein the first formulation comprises cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids, and an excipient; wherein the primary cannabinoids in the first formulation comprise or consist of, on a weight % basis: 17%-54% CBC; and 46%-83% CBD; and
wherein the second formulation comprises tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids, and an excipient; wherein the primary cannabinoids in the second formulation comprise or consist of, on a weight % basis: 30%-45% THC; 9%-35% CBC; and 30%-45% CBD.

### Claim 2 (depends on 1)

The formulation pairing of claim 1, wherein the pain management comprises treatment of pain due to cancer, injury, accident, surgery, inflammation, tissue damage, arthritis, joint pain, pain from infection, gastrointestinal pain, diabetes, diabetes neuropathy, post-shingles neuralgia, neuropathic pain, peripheral neuropathy or multiple sclerosis.

### Claim 3 (depends on 1)

The formulation pairing of claim 1, wherein:
the primary cannabinoids are present in the first formulation in amounts according to a ratio of CBC:CBD ranging from 1:5 to 5:5, and
the primary cannabinoids are present in the second formulation in amounts according to a ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5.

### Claim 4 (depends on 1)

The formulation pairing of claim 1, wherein the first and second formulations are prepared in a dosage form selected from the group consisting of a pill, tablet, gel capsule, syrup, oil-based spray, and liquid oil form.

### Claim 5 (depends on 1)

The formulation pairing of claim 1, wherein the first and second formulations provide a total amount of from about 1 mg to about 25 mg of primary cannabinoid per dose.

### Claim 6 (depends on 1)

The formulation pairing of claim 1, provided as a kit comprising instructions for use in a multi-dose daily regimen.